Clinical Trial Update: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations [Phase 3]

View source ↗

Summary

Phase III trial comparing Nazartinib to Erlotinib/Gefitinib in first-line locally advanced/metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gefitinib (Gefitinib)
• Nazartinib (EGF816) (Nazartinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-small Cell Lung | Phase 3 | Status: WITHDRAWN